There are 2867 resources available
1487MO - A pan-sarcoma investigation of genetic alterations associated with high telomeric content
Presenter: Radwa Sharaf
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
621MO - Preclinical study of DASH CAR-T cells manufactured in 48 hours
Presenter: Haiying Wang
Session: Mini Oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
932MO - Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
Presenter: Enriqueta Felip
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1492MO - Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS)
Presenter: Tom Wei-Wu Chen
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
622MO - An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
Presenter: EUNHEE LEE
Session: Mini Oral session: Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial
Presenter: Come Lepage
Session: Mini Oral session: GI, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 320MO and LBA28
Presenter: Pia Osterlund
Session: Mini Oral session: GI, lower digestive
Resources:
Slides
Webcast
Invited Discussant 621MO and 622MO
Presenter: Irit Avivi
Session: Mini Oral session: Haematological malignancies
Resources:
Slides
Webcast
1493MO - Peripheral immune biomarkers of survival in patients with resectable dedifferentiated liposarcomas (DDLPS) and undifferentiated pleomorphic sarcomas (UPS) treated with neoadjuvant nivolumab +/- ipilimumab (neoICB)
Presenter: Elise Nassif
Session: Mini Oral session: Sarcoma
Resources:
Abstract
Slides
Webcast
LBA50 - Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
Presenter: Janis Taube
Session: Mini Oral session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast